Coprexa Approval Status
- FDA approved: No
- Brand name: Coprexa
- Generic name: tetrathiomolybdate
- Company: Pipex Pharmaceuticals, Inc.
- Treatment for: Wilson's Disease
Coprexa (tetrathiomolybdate) is an oral, small-molecule, anti-copper agent intended for the treatment of initially presenting neurologic Wilson’s disease.
In January 2008, Pipex Pharmaceuticals, Inc. announced the receipt of a Refusal to File Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for Coprexa (oral tetrathiomolybdate) had not been accepted by the FDA for further review as submitted.
Development Status and FDA Approval Process for Coprexa
|Jan 29, 2008||Pipex Pharmaceuticals Provides Update on Coprexa (Oral Tetrathiomolybdate) New Drug Application|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.